We next determined whether or not these four Lck peptides, which were more frequently recognised by IgGs in cancer patients than were the other 17 peptides, could induce peptide-specific CTLs from the PBMCs of HLA-A11+, -A31+, or -A33+ prostate cancer patients. The gene discussed is LCK; the disease is prostate carcinoma.